VSTM Q2 2021 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$500,000-88.4% YoY

Gross Profit

$500,000100.0% margin

Operating Income

-$16M-3188.8% margin

Net Income

-$17M-3380.4% margin

EPS (Diluted)

$-1.20

QoQ Revenue Growth

-50.3%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$124M

Total Liabilities

$36M

Stockholders' Equity

$88M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$500,000	$4M	-88.4%
Gross Profit	$500,000	$4M	-85.8%
Operating Income	-$16M	-$21M	+25.0%
Net Income	-$17M	-$23M	+26.5%

Revenue Segments

Product Revenue And Allowances Returns

$28,00088%

Product Revenue Reserves And Allowances Trade Discounts And Allowances

$4,00013%